Pinnacle Associates’s GSK GSK Stock Holding History

Pinnacle Associates’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.09M	Sell	20,791 -773	-4%	-$40.9K	0.01%	518
2026 Q1	$1.19M	Sell	21,564 -793	-4%	-$43K	0.02%	489
2025 Q4	$1.1M	Sell	22,357 -513	-2%	-$23.9K	0.01%	501
2025 Q3	$987K	Sell	22,870 -233	-1%	-$9.1K	0.01%	515
2025 Q2	$887K	Sell	23,103 -2,306	-9%	-$88.1K	0.01%	529
2025 Q1	$984K	Sell	25,409 -606	-2%	-$22.2K	0.01%	492
2024 Q4	$880K	Sell	26,015 -6,906	-21%	-$249K	0.01%	504
2024 Q3	$1.22M	Buy	32,921 +1,912	+6%	+$78.2K	0.02%	434
2024 Q2	$1.19M	Sell	31,009 -465	-1%	-$19.6K	0.02%	440
2024 Q1	$1.35M	Sell	31,474 -1,447	-4%	-$59.7K	0.02%	431
2023 Q4	$1.22M	Sell	32,921 -1,942	-6%	-$69.7K	0.02%	441
2023 Q3	$1.26M	Sell	34,863 -1,149	-3%	-$40.8K	0.02%	420
2023 Q2	$1.28M	Buy	36,012 +152	+0.4%	+$5.45K	0.02%	429
2023 Q1	$1.28M	Sell	35,860 -2,970	-8%	-$104K	0.03%	374
2022 Q4	$1.36M	Sell	38,830 -1,368	-3%	-$45.6K	0.03%	354
2022 Q3	$1.18M	Buy	+40,198	New	+$1.52M	0.03%	366
2022 Q2	–	Sell	-37,902	Closed	-$2.06M	–	768
2022 Q1	$2.06M	Buy	37,902 +729	+2%	+$39.6K	0.04%	340
2021 Q4	$2.05M	Sell	37,173 -455	-1%	-$23.7K	0.04%	344
2021 Q3	$1.8M	Sell	37,628 -262	-0.7%	-$13.2K	0.03%	355
2021 Q2	$1.89M	Sell	37,890 -886	-2%	-$42.6K	0.03%	342
2021 Q1	$1.73M	Buy	38,776 +6,314	+19%	+$287K	0.03%	348
2020 Q4	$1.49M	Sell	32,462 -2,255	-6%	-$104K	0.03%	343
2020 Q3	$1.63M	Buy	34,717 +1,644	+5%	+$82.4K	0.04%	306
2020 Q2	$1.69M	Sell	33,073 -1,715	-5%	-$88K	0.04%	296
2020 Q1	$1.65M	Buy	34,788 +6,023	+21%	+$321K	0.05%	277
2019 Q4	$1.69M	Sell	28,765 -546	-2%	-$30.4K	0.04%	327
2019 Q3	$1.56M	Sell	29,311 -4,831	-14%	-$249K	0.04%	338
2019 Q2	$1.71M	Sell	34,142 -835	-2%	-$41.9K	0.04%	327
2019 Q1	$1.83M	Buy	34,977 +119	+0.3%	+$5.95K	0.04%	315
2018 Q4	$1.67M	Buy	34,858 +1,744	+5%	+$85.9K	0.04%	315
2018 Q3	$1.66M	Sell	33,114 -2,550	-7%	-$130K	0.03%	340
2018 Q2	$1.8M	Sell	35,664 -172	-0.5%	-$8.66K	0.04%	320
2018 Q1	$1.75M	Sell	35,836 -935	-3%	-$43.5K	0.03%	327
2017 Q4	$1.63M	Sell	36,771 -702	-2%	-$32.4K	0.03%	332
2017 Q3	$1.9M	Buy	37,473 +1,907	+5%	+$96.7K	0.04%	313
2017 Q2	$1.92M	Buy	35,566 +450	+1%	+$24K	0.04%	311
2017 Q1	$1.85M	Sell	35,116 -892	-2%	-$45.3K	0.04%	327
2016 Q4	$1.73M	Sell	36,008 -2,320	-6%	-$115K	0.04%	323
2016 Q3	$2.07M	Sell	38,328 -550	-1%	-$30.2K	0.04%	301
2016 Q2	$2.11M	Buy	38,878 +5	+0%	+$263	0.05%	291
2016 Q1	$1.97M	Sell	38,873 -111	-0.3%	-$5.53K	0.04%	285
2015 Q4	$1.97M	Buy	38,984 +843	+2%	+$43K	0.04%	280
2015 Q3	$1.83M	Sell	38,141 -41	-0.1%	-$2.13K	0.04%	289
2015 Q2	$1.99M	Buy	38,182 +2,159	+6%	+$122K	0.04%	290
2015 Q1	$2.08M	Sell	36,023 -91	-0.3%	-$5.22K	0.04%	280
2014 Q4	$1.93M	Sell	36,114 -220	-0.6%	-$12.3K	0.04%	285
2014 Q3	$2.09M	Buy	36,334 +5,277	+17%	+$324K	0.04%	278
2014 Q2	$2.08M	Sell	31,057 -439	-1%	-$29.7K	0.04%	285
2014 Q1	$2.1M	Buy	31,496 +4,122	+15%	+$279K	0.04%	273
2013 Q4	$1.83M	Sell	27,374 -1,542	-5%	-$100K	0.04%	301
2013 Q3	$1.81M	Sell	28,916 -1,573	-5%	-$101K	0.04%	287
2013 Q2	$1.9M	Buy	+30,489	New	+$1.94M	0.04%	274

Other funds holding GSK

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.25B AUM 41.83% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Pinnacle Associates's GSK Position: Q2 2026 in Review

Pinnacle Associates reduced its GSK (GSK) stake by 3.6% in Q2 2026, selling an estimated $40.9K and leaving 20,791 shares worth $1.09M. The position accounts for 0.01% of the portfolio, ranked #518.

Pinnacle Associates first reported a position in GSK in Q2 2013 and has held it in 52 quarters since. The position peaked at $2.11M in Q2 2016. 1,037 funds tracked by Wall St. Rank hold GSK as of Q2 2026.

Pinnacle Associates held 20,791 shares of GSK worth $1.09M as of Q2 2026.
Pinnacle Associates sold 773 GSK shares in Q2 2026, an estimated $40.9K.
GSK made up 0.01% of Pinnacle Associates's portfolio in Q2 2026, its #518 holding.
Pinnacle Associates first reported a position in GSK in Q2 2013 and has held it in 52 quarters since.
Pinnacle Associates's GSK position peaked at $2.11M in Q2 2016.
1,037 funds tracked by Wall St. Rank held GSK as of Q2 2026.

Based on Pinnacle Associates's 13F filing for Q2 2026, filed 3 Aug 2026.